In 2021, Birnbaum et al. (20) and Ingoe et al. (23) demonstrated increased diagnosis of FH and utilization of genetic testing after system-wide scanning of the EHR to identify patients at high risk; and Soper et al. (59) described a genomic screening program that identified individuals with variants in TTR, none of whom had a previous diagnosis of hereditary transthyretin amyloidosis. The gene discussed is TTR; the disease is Familial transthyretin-related amyloidosis.